Global Asthma Drugs Market Size, Share, Trends, and Forecast 2026-2035 | Biologics, Pediatric Expansion, and Asia-Pacific Demand Drive Growth to USD 41.18 Billion

Dublin, Oct. 16, 2026 -- "Asthma Drugs Market by Mode of Administration; Medication; Application; Organization Type; Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035" has been added to ResearchAndMarkets.com's offering.

The global asthma drugs market is shifting from high-volume inhaler dependence toward targeted, high-value therapies. According to the report, the market was valued at approximately USD 26.52 billion in 2025 and is projected to reach USD 41.18 billion by 2035, expanding at a CAGR of 4.50% from 2026 to 2035. This growth highlights the strategic importance of asthma therapeutics within the global respiratory care industry.

Market expansion is supported by the rising prevalence of chronic respiratory inflammation, rapid urbanization, and greater exposure to air pollution and allergens. Demand is also increasing for precision-based treatments, particularly biologics for patients with moderate to severe asthma who remain uncontrolled despite conventional inhaled therapies.

Asthma Drugs Market Developments

Leading pharmaceutical companies are strengthening their asthma drug portfolios through product development, regulatory approvals, combination therapies, and lifecycle management. AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Teva, and Viatris are among the companies influencing current treatment standards and the future direction of asthma care.

Fixed-dose combinations of bronchodilators and corticosteroids remain central to asthma management. These products address bronchoconstriction and airway inflammation while supporting treatment adherence. At the same time, biologics targeting specific inflammatory pathways are gaining commercial and clinical importance in severe asthma treatment.

In December 2025, GSK secured FDA approval for Exdensur, a long-acting biologic developed to provide sustained asthma symptom control. The approval demonstrates the pharmaceutical industry's growing focus on advanced therapies that can improve outcomes for patients inadequately controlled with established medications.

Key Market Growth Drivers

Asia-Pacific is emerging as an important growth market due to rising pollution-related respiratory disease, industrial emissions, rapid urbanization, particulate exposure, and seasonal allergens. Thunderstorm Asthma events, which can cause sudden increases in severe asthma cases, further emphasize the need for accessible maintenance therapies, emergency medications, and advanced treatment options across the region.

Pediatric biologics represent another significant market opportunity. Regulatory agencies, including the FDA and EMA, are expanding the approved age ranges for selected targeted therapies. Dupixent (dupilumab), approved for children aged six and older, supports earlier intervention for pediatric patients with severe or uncontrolled asthma. Continued regulatory progress could expand the eligible patient population and accelerate innovation in pediatric asthma treatment.

Market Challenges

Generic competition remains a major constraint for branded asthma drug manufacturers. Authorized generics for Budesonide/Formoterol and related combinations are increasing pricing pressure on established products such as Symbicort and Advair. This trend is reducing branded revenue potential and intensifying competition across the maintenance therapy segment.

Manufacturers are responding by prioritizing differentiated products, biologics, improved delivery systems, and treatments supported by clinical biomarkers. However, the higher cost of advanced therapies and varying reimbursement conditions may limit adoption in some healthcare systems.

Asthma Drugs Market Segmentation

Inhalers account for the dominant revenue share by mode of administration, supported by direct pulmonary delivery, rapid onset, established prescribing practices, and broad use in maintenance and rescue treatment. Quick Relief Medications, primarily short-acting beta-agonists (SABAs), hold the largest medication share due to widespread use during acute symptom episodes and environmentally triggered exacerbations.

The Public segment is expected to lead by organization type, reflecting substantial demand among elderly, lower-income, and medically complex populations that rely on publicly funded healthcare. Adults remain the largest application segment, supported by higher use of biomarker-guided therapies and targeted biologics.

• By Medication: Quick Relief Medications, Long-term Control Medications, Others
• By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections
• By Organization Type: Public, Private
• By Application: Pediatric, Adults, Adolescent
• By Region: North America, Europe, Asia-Pacific, Middle East and Africa, South America

Regional Market Outlook

North America is expected to retain its leading position, accounting for approximately 47% of the global asthma drugs market. The United States supports regional growth through advanced healthcare infrastructure, high diagnosis rates, substantial pharmaceutical research activity, and strong adoption of biologics for severe asthma.

Pricing, reimbursement, and formulary access remain important considerations in the U.S. market. Pharmacy Benefit Manager rebate structures influence product placement and therapy adoption, while Inflation Reduction Act drug price negotiations beginning in 2026 may affect broader pharmaceutical pricing strategies. Although the initial negotiated products primarily address cardiovascular disease and diabetes, the evolving policy environment may influence investment and commercialization decisions across respiratory therapeutics.

Competitive Landscape

The asthma drugs market includes multinational pharmaceutical companies, specialty drug developers, and generic manufacturers. Prominent participants include AbbVie Inc., Amgen Inc., AstraZeneca, Boehringer Ingelheim Intl. GmbH, Chiesi Farmaceutici S.p.A., Cipla Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, and Viatris Inc. (Mylan).

Future market performance will be shaped by biologic innovation, pediatric label expansion, combination therapy development, generic competition, reimbursement policies, and increasing respiratory disease prevalence. Companies that deliver clinically differentiated treatments while addressing affordability and access will be best positioned to capture growth through 2035.

Report Attribute	Details
No. of Pages	260
Forecast Period	2025-2035
Estimated Market Value (USD) in 2025	$26.52 Billion
Forecasted Market Value (USD) by 2035	$41.18 Billion
Compound Annual Growth Rate	4.5%
Regions Covered	Global

For more information about this report visit https://www.researchandmarkets.com/r/jt6lbp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.